Drugs / MIL97
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04965077 | Jan 2022 → Dec 2025 overdue | — | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06255912 Background | Mar 2024 → Mar 2029 expected | malignant pancreatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIL-97 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06255912 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Monoclonal Antibody MIL97 for Injection” NCT04965077 ↗ |
| Route | Intravenous | “Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle” NCT04965077 ↗ |